§ Specialty

Fertility SEO

Fertility SEO.

Abstract

The success-rate claim is the most regulated surface in medical marketing. SART data and the CDC ART Success Rates Report are the citation sources. State medical board rules prohibit superlatives and govern typicality representations. The REI fellowship surfaces in the author byline. The FDA HCT/P framework applies to donor programs. Every claim has a source or it does not ship.

Book a diagnostic →

Fertility sits inside our agency's broader medical SEO practice. The work integrates with the consent-workflow design, the case-study path under 45 CFR 164.514, the per-subspecialty editorial architecture, and the schema discipline that reserves clinical types for REI-authored editorial.

What governs the surface

Four regulatory surfaces. Success rates, state rules, subspecialty byline, HCT/P.

Fertility marketing intersects the federal success-rate-reporting mandate, state medical board rules on superlatives and typicality, ABMS specialty alignment at the REI subspecialty level, and the FDA HCT/P framework where donor programs enter the page. Each surface has its own source-of-claim discipline.

SART and CDC ART Success Rates Report mechanics.

The Society for Assisted Reproductive Technology (SART) collects clinic-level data that feeds the CDC ART Success Rates Report mandated by the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA). The CDC publishes the data annually with the methodology and caveats specified. Success-rate claims on a fertility practice's website carry citation back to the SART data, the CDC report, or both, with the reporting year named. Aggregate practice claims that diverge from the SART data without naming the methodological reason read as unsupported under state medical board advertising rules. The reporting source is the citation surface.

State medical board rules on superlatives and typicality representations.

State medical board advertising rules layer additional specificity on AMA Opinion E-9.6.1. The fertility-specific surface intersects two rule categories. Superlative framings cross the prohibition in most states regardless of supporting data. Typicality representations on success-rate claims require disclaimer language per state (Florida testimonial-typicality, California Business and Professions Code disclaimer rules, Texas Medical Board, New York). Multi-state fertility groups clear the strictest market on every page. The per-state rule overlay sits in the page-level disclosure pattern.

ABMS American Board of Obstetrics and Gynecology plus REI subspecialty.

Reproductive Endocrinology and Infertility (REI) is the ABMS subspecialty for IVF practice. The Reviews System 2023+ medical-content framework reads ABMS American Board of Obstetrics and Gynecology certification with the REI subspecialty fellowship alignment on first-party editorial content. The Physician.sameAs JSON-LD chain reaches the ABMS verification page, the NPPES (NPI registry) entry, the state medical board licensure profile, and the SART clinic membership page where the REI subspecialty surfaces verifiably. Editorial content authored by a non-REI generalist obstetrician on IVF protocols is the documented YMYL-demotion pattern.

21 CFR 1271 on the reproductive-tissue surface, distinct from prescription drug advertising.

Fertility marketing intersects FDA regulation at the human cells, tissues, and cellular and tissue-based products (HCT/P) surface under 21 CFR 1271, not the prescription drug advertising surface at 21 CFR 202. The HCT/P framework governs the donor-screening, donor-eligibility, and tissue-handling practices the clinic discloses. The page architecture separates HCT/P-mentioning content (donor egg programs, donor sperm programs, embryo donation surfaces) from generic IVF service marketing. Where ovulation-induction medications surface by trade name (Gonal-F, Follistim, Menopur), the FDA 21 CFR 202 boundary applies separately, with the fair-balance pattern.

Side by side

Fertility on Praxis versus the aggressive-claim template default, on the surfaces where the regulatory scrutiny lands.

Fertility practice on Praxis

Success-rate and credential disciplined

Fertility practice on generalist SEO

Aggressive-claim template default

Success-rate claim sourcing

Every success-rate claim carries SART or CDC ART Success Rates Report citation with the reporting year named. Practice-internal aggregate claims that diverge from the SART data name the methodological reason. Per-patient typicality framing applied per state.

Success-rate claims published without source. Superlative framings shipped under state medical board prohibitions. Typicality framing absent.

Author byline subspecialty alignment

ABMS American Board of Obstetrics and Gynecology with the REI subspecialty fellowship surfaced in the byline. Physician.sameAs chain reaches ABMS, NPPES, state board, SART clinic membership. Reviews System reads the topic-to-credential alignment on IVF editorial content.

Generic agency byline or generalist obstetrician byline without REI fellowship surfacing. Reviews System framework reads no REI-aligned practicing reviewer signal.

HCT/P donor-program content

Donor egg, donor sperm, embryo donation surfaces architected as 21 CFR 1271 HCT/P content. Donor-screening, eligibility, tissue-handling disclosure aligned with the framework. Separated from generic IVF service marketing pages architecturally.

Donor-program content mixed with generic IVF service pages. HCT/P framework references absent. Donor-screening disclosure pattern unspecified.

Ovulation-induction medication copy

Gonal-F, Follistim, Menopur, Clomid trade-name surfaces architected as 21 CFR 202 promotional copy. Fair-balance pattern applied. State-board advertising rules layered on top.

Trade-name surfaces published as treatment-protocol commentary. Fair-balance pattern absent. FDA boundary unread.

Schema markup discipline

Commercial pages on MedicalBusiness with availableService nodes listing the service offerings. MedicalProcedure schema reserved for editorial content authored by REI-fellowship-credentialed physicians.

MedicalProcedure schema applied to commercial pages selling IVF cycles, frozen embryo transfers, donor egg programs. Spammy-structured-data manual-action pattern is the documented outcome.

Patient testimonial workflow

45 CFR 164.508 written-authorization template plus per-state typicality framing for success-rate-adjacent testimonials. De-identified case studies for outcome-trajectory content route through 164.514 Safe Harbor separately.

Patient quotes shipped without consent record. Identifiable success-story testimonials carry HIPAA exposure plus state-board typicality exposure simultaneously.

Fertility practice on Praxis

Success-rate and credential disciplined

Success-rate claim sourcing: Every success-rate claim carries SART or CDC ART Success Rates Report citation with the reporting year named. Practice-internal aggregate claims that diverge from the SART data name the methodological reason. Per-patient typicality framing applied per state.
Author byline subspecialty alignment: ABMS American Board of Obstetrics and Gynecology with the REI subspecialty fellowship surfaced in the byline. Physician.sameAs chain reaches ABMS, NPPES, state board, SART clinic membership. Reviews System reads the topic-to-credential alignment on IVF editorial content.
HCT/P donor-program content: Donor egg, donor sperm, embryo donation surfaces architected as 21 CFR 1271 HCT/P content. Donor-screening, eligibility, tissue-handling disclosure aligned with the framework. Separated from generic IVF service marketing pages architecturally.
Ovulation-induction medication copy: Gonal-F, Follistim, Menopur, Clomid trade-name surfaces architected as 21 CFR 202 promotional copy. Fair-balance pattern applied. State-board advertising rules layered on top.
Schema markup discipline: Commercial pages on MedicalBusiness with availableService nodes listing the service offerings. MedicalProcedure schema reserved for editorial content authored by REI-fellowship-credentialed physicians.
Patient testimonial workflow: 45 CFR 164.508 written-authorization template plus per-state typicality framing for success-rate-adjacent testimonials. De-identified case studies for outcome-trajectory content route through 164.514 Safe Harbor separately.

Fertility practice on generalist SEO

Aggressive-claim template default

Success-rate claim sourcing: Success-rate claims published without source. Superlative framings shipped under state medical board prohibitions. Typicality framing absent.
Author byline subspecialty alignment: Generic agency byline or generalist obstetrician byline without REI fellowship surfacing. Reviews System framework reads no REI-aligned practicing reviewer signal.
HCT/P donor-program content: Donor-program content mixed with generic IVF service pages. HCT/P framework references absent. Donor-screening disclosure pattern unspecified.
Ovulation-induction medication copy: Trade-name surfaces published as treatment-protocol commentary. Fair-balance pattern absent. FDA boundary unread.
Schema markup discipline: MedicalProcedure schema applied to commercial pages selling IVF cycles, frozen embryo transfers, donor egg programs. Spammy-structured-data manual-action pattern is the documented outcome.
Patient testimonial workflow: Patient quotes shipped without consent record. Identifiable success-story testimonials carry HIPAA exposure plus state-board typicality exposure simultaneously.

Updated 2026-05-28

How we engage

Diagnostic, then monthly retainer. Four phases, each scoped against cited deliverables.

Weeks 0-2

Diagnostic

We read your Search Console data, your traffic data, your current Schema.org markup, your physician author bylines, your testimonial pages, and your directory-profile completeness. The diagnostic comes back with the load-bearing pages, the dead weight, the YMYL-fragile content, and the entity-graph gaps. For multi-location groups, we add a GBP audit per practicing location.
Weeks 2-6

Schema and author layer

We build the MedicalBusiness and Physician schema layer with sameAs chains to NPI registry, ABMS verification, and state medical board profiles. Author bylines surface ABMS specialty and active state license alignment. CPT-aligned service pages where the procedure mix supports it. The schema layer reflects what each page actually is, MedicalCondition / MedicalProcedure types reserved for the editorial layer.
Weeks 4-8

Reviews System alignment

Editorial content rebuilt against the Reviews System 2023+ medical-content framework. Practicing-physician reviewer signals on first-party content. PubMed-cited primary literature replacing health-magazine summaries. Topic-to-specialty alignment in every author byline (a general practitioner does not author complex oncological articles). Patient testimonial workflow routed through the 45 CFR 164.508 consent path before any testimonial lands on a service page.
Monthly

Ongoing retainer

Monthly cadence on the rest of the site, plus content cadence for the queries the diagnostic surfaced. Quarterly review against your traffic data and Search Console movement. Re-audit of the entity-graph reconciliation when physician rosters change. Re-audit of the consent workflow when state medical board advertising rules change.

Common questions

Questions practice administrators ask before booking a diagnostic.

01.

Our clinic's success rates are higher than the regional average. How do we surface that?

Every success-rate claim carries citation. The Society for Assisted Reproductive Technology (SART) collects clinic-level data that feeds the CDC ART Success Rates Report under the Fertility Clinic Success Rate and Certification Act of 1992. The CDC publishes annually with methodology specified. Practice-internal aggregate claims that diverge from the SART data name the methodological reason (different patient-population mix, different age-stratified cohorts, different treatment-cycle inclusion criteria). State medical board advertising rules prohibit superlative framings (best, highest, top, leading) regardless of supporting data. Per-state typicality framing applies on testimonial-adjacent claims. The page presents the SART-cited claim with the methodology context and the per-state disclaimer; the superlative framing does not appear on the page.

02.

Our REI fellowship surgeons author all IVF editorial content. Is the byline enough?

The Reviews System 2023+ medical-content framework reads three signals on first-party editorial: practicing-physician reviewer status, ABMS specialty alignment with the article topic, active state license. For IVF content, the alignment runs through ABMS American Board of Obstetrics and Gynecology certification with the Reproductive Endocrinology and Infertility (REI) subspecialty fellowship. The byline surfaces the name and the fellowship; the JSON-LD Physician.sameAs chain ties the byline to the ABMS verification page, the NPPES NPI registry entry, the state medical board licensure profile, and the SART clinic membership where the REI subspecialty surfaces verifiably. The byline becomes the surface; the chain becomes the proof.

03.

We run donor egg and donor sperm programs. How do those surfaces differ from generic IVF marketing?

The donor programs surface intersects FDA regulation under 21 CFR 1271 for human cells, tissues, and cellular and tissue-based products (HCT/P). The framework governs donor-screening, donor-eligibility, tissue-handling, and disclosure practices the clinic surfaces in marketing. The page architecture separates HCT/P-mentioning content (donor egg, donor sperm, embryo donation) from generic IVF service marketing so the regulatory references and the disclosure pattern remain attached to the donor-program pages where they apply. Generic IVF service pages do not carry HCT/P references unless the page substantively addresses donor-program content.

04.

We mention Gonal-F and Follistim on our protocol pages. Are we in FDA territory?

A fertility practice marketing its own services is not advertising a prescription drug, and the FDA fair-balance framework does not bind the practice the way it binds the pharmaceutical manufacturer. The moment the page mentions Gonal-F, Follistim, Menopur, Clomid, or another ovulation-induction medication by trade name in a promotional context, the surface crosses into FDA-regulated promotional copy under 21 CFR 202. The fair-balance requirement applies: efficacy claims pair with risk information. The page architecture separates protocol-education content (no trade names, generic-drug-class language like 'recombinant FSH' or 'clomiphene citrate') from prescription-drug-mentioning content (fair-balance pattern applied).

05.

How does the per-state typicality rule sit alongside the SART citation?

Two distinct compliance surfaces. The SART/CDC citation is the source-of-data discipline; the success-rate claim is cited to the reporting body with the year and the methodology context. The per-state typicality rule is the per-patient framing discipline; where the success-rate claim sits adjacent to a patient testimonial or success story, the per-state disclaimer language (Florida testimonial-typicality, California Business and Professions Code, Texas, New York) carries the typicality framing on the page. Multi-state practices clear the strictest market on every page. The two surfaces stack: aggregate practice success rates cite SART; per-patient success stories carry per-state typicality framing alongside the 45 CFR 164.508 consent record.

06.

Does Praxis author the medical-substance content?

We author the SEO architecture, the schema layer, the editorial structure, and the regulatory framing around clinical content. The medical-substance content (IVF protocol descriptions, candidacy criteria, treatment-cycle mechanics) is authored or reviewed by the REI-fellowship-credentialed reproductive endocrinologist at the practice, with the author byline reflecting that. Praxis as an entity does not provide medical advice or treatment, and the footer disclaimer states it directly.

Stop watching your competitors rank

If your success-rate claims ship without a SART or CDC ART citation, the state board reads them as advertising violations.

The diagnostic audits every success-rate claim against SART and CDC ART Success Rates Report sourcing, every editorial article against ABMS Obstetrics and Gynecology with REI subspecialty alignment, every donor-program page against the FDA HCT/P framework, and the per-state superlative and typicality overlay for every state the practice operates in.

Book a diagnostic → Email us